Tags

Type your tag names separated by a space and hit enter

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 18; 69(50):1922-1924.MM

Abstract

On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania), a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,† using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.§ The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33332292

Citation

Oliver, Sara E., et al. "The Advisory Committee On Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020." MMWR. Morbidity and Mortality Weekly Report, vol. 69, no. 50, 2020, pp. 1922-1924.
Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924.
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., Romero, J. R., Talbot, H. K., Lee, G. M., Bell, B. P., & Dooling, K. (2020). The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR. Morbidity and Mortality Weekly Report, 69(50), 1922-1924. https://doi.org/10.15585/mmwr.mm6950e2
Oliver SE, et al. The Advisory Committee On Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. PubMed PMID: 33332292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. AU - Oliver,Sara E, AU - Gargano,Julia W, AU - Marin,Mona, AU - Wallace,Megan, AU - Curran,Kathryn G, AU - Chamberland,Mary, AU - McClung,Nancy, AU - Campos-Outcalt,Doug, AU - Morgan,Rebecca L, AU - Mbaeyi,Sarah, AU - Romero,José R, AU - Talbot,H Keipp, AU - Lee,Grace M, AU - Bell,Beth P, AU - Dooling,Kathleen, Y1 - 2020/12/18/ PY - 2020/12/17/entrez PY - 2020/12/18/pubmed PY - 2020/12/19/medline SP - 1922 EP - 1924 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 69 IS - 50 N2 - On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania), a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,† using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.§ The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/33332292/The_Advisory_Committee_on_Immunization_Practices'_Interim_Recommendation_for_Use_of_Pfizer_BioNTech_COVID_19_Vaccine___United_States_December_2020_ L2 - https://doi.org/10.15585/mmwr.mm6950e2 DB - PRIME DP - Unbound Medicine ER -